
样式: 排序: IF: - GO 导出 标记为已读
-
Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-17 Jonggi Choi
We appreciate the interest of Salimi and Liu in our study on variceal bleeding (VB) risk in patients receiving atezolizumab–bevacizumab (Atezo–Bev) for hepatocellular carcinoma (HCC) and their insightful comments highlighting the importance of risk stratification [1, 2]. We fully concur that VB risk factors should not be overlooked and that a patient-specific risk approach is crucial in clinical decision-making
-
Association of Healthy Lifestyle Behaviours With Incident Inflammatory Bowel Disease: A Population-Based Prospective Cohort Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-17 Fai Fai Ho, Yin-Yan Gao, Yuting Chen, Betty Huan Wang, Justin Che Yuen Wu, Hong Zheng, Yin Ting Cheung, Chun Sing Lam, Maggie Haitian Wang, Irene Xin-Yin Wu, Chen Mao, Vincent Chi Ho Chung
-
Editorial: Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab for Hepatocellular Carcinoma: Don't Ignore the Risk Factors! Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-17 Shirin Salimi, Ken Liu
The introduction of immunotherapy has changed the treatment paradigm for unresectable hepatocellular carcinoma (HCC) [1]. The landmark IMbrave150 trial demonstrated improved overall survival with atezolizumab-bevacizumab against sorafenib for unresectable HCC [2]. All patients underwent gastroscopy within 6 months prior to trial initiation and those with high-risk varices were excluded. Despite this
-
Letter on ‘Head-To-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’ Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-17 Federica Tavaglione, Rohit Loomba
We thank Abubakr and colleagues [1] for their supportive comments on our recently published work, where we show that phosphatidylethanol (PEth) is a precise, quantitative, objective alcohol biomarker for differentiating metabolic dysfunction and alcohol-related liver disease (MetALD) from metabolic dysfunction-associated steatotic liver disease (MASLD). Notably, PEth exhibited robust diagnostic accuracy
-
Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-16 Erin R. Bonner, Werner Tschollar, Robert Anderson, Sulayman Mourabit
-
Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-16 Soon Sun Kim, Jonghyun Lee, Sang Bong Ahn, Young Eun Chon, Eileen Yoon, Soung Won Jeong, Dae Won Jun
-
Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-15 Federica Tavaglione, Rohit Loomba
We thank Ho and Mak for their positive comments on our recently published work, in which we demonstrate that phosphatidylethanol (PEth) is an accurate, quantitative, objective, blood-based alcohol biomarker for diagnosing the newly defined metabolic dysfunction and alcohol-related liver disease (MetALD) [1]. Leveraging a well-characterised United States (U.S.) cohort of 374 community-dwelling individuals
-
Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-15 Tim Eglinton
Perianal fistulising Crohn's disease (PFCD), a chronic debilitating condition affecting a third of patients with CD [1], carries substantial associated morbidity and negatively impacts quality of life (QoL). The three basic tenets of PFCD management have been to drain sepsis, control inflammation and heal the fistula, if appropriate. The caveat is attached to the third tenet because not all Crohn's
-
Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-15 Xueneng Yang, Ruijuan Li
Editors, Inflammatory bowel disease (IBD) has shown a significant rise in global incidence over the past few decades, with particularly rapid increase in children and adolescents [1, 2]. Early-life antibiotic use has profound effects on the gut microbiome and immune system, linking it to an elevated risk of IBD [1, 3]. Despite growing research, the specific impacts of different antibiotic types, doses
-
Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-15 Marco Mendolaro, Marco Daperno
Endoscopic activity is one of the most relevant prognostic markers in Crohn's disease: worse endoscopic features and more severe endoscopic activity are associated with poorer outcomes, while healing of lesions is associated with more favourable outcomes [1, 2]. While most available evidence on the prognostic role of endoscopic activity is based on data from moderately to severely active Crohn's disease
-
Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-15 Karen Cheuk‐Ying Ho, Lung‐Yi Mak
The recent re-naming and reclassification of ‘non-alcoholc fatty liver disease (NAFLD)’ to steatotic liver disease (SLD) subcategories aims to clarify the different aetiologies associated with liver fat accumulation, particularly alcohol consumption and/or metabolic dysfunction [1]. A novel entity, coined as ‘metabolic and alcohol related/associated liver disease (MetALD)’ was introduced to capture
-
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-14 Ying‐Nan Tsai, Jia‐Ling Wu, Yao‐Chun Hsu
We sincerely appreciate Dr. Mauss's comments on our study recently published in the journal, [1] which examined the association between alanine transaminase (ALT) elevation and HBsAg seroclearance following cessation of nucleos(t)ide analogue (NA) therapy [2]. Because HBsAg seroclearance rarely occurs during NA therapy, treatment cessation without requiring HBsAg seroclearance has been proposed as
-
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-14 Stefan Mauss
Given the lack of treatment options beyond viral suppression the strategy of inducing hepatitis B surface antigen (HBsAg) loss after stopping therapy with hepatitis B virus (HBV) polymerase inhibitors is an increasingly attractive concept. Inducing immune responses in a sizeable minority of patients leading to HBsAg loss were reported in studies [1, 2]. The paper by Tsai et al. focuses on the relevance
-
Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-14 Kee Huat Chuah, Sanjiv Mahadeva
We thank Dr. Miyahara et al. for their interest in our paper [1] and for their constructive comments [2]. We agree that certain aspects of the study design could be improved to enhance its robustness. Placebo-controlled studies are widely regarded as the gold standard for evaluating the efficacy and safety of drugs. However, in the context of functional dyspepsia (FD), numerous placebo-controlled trials
-
Issue Information Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-14
Click on the article title to read more.
-
Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-14 Luis Antonio Diaz, Sheldon Morris, Shravan Dave, Susy M. Kim, Wathnita Sarik, Lisa Richards, Egbert Madamba, Ricki Bettencourt, Christian Fulinara, Thuy Pham, Grant Miller, Raquel Carvalho‐Gontijo Weber, Jeremiah D. Momper, Feng He, Sonia Jain, Catriona Jamieson, Tatiana Kisseleva, David Brenner, Rohit Loomba
-
Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-14 Shoko Miyahara, Takeshi Yamashina, Takehiro Ohyama, Masahiro Banno
The study by Chuah et al. [1] offers valuable insight that can significantly influence daily outpatient practice. The findings, while valuable, suggest that certain aspects of the study's design and scope could benefit from further refinement to guide future research effectively. First, the absence of blinding and a placebo group may have contributed to an overestimation of the observed efficacy in
-
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-13 Amrik Shah, Leigh MacConell, Alexander Liberman, Adrian M. Di Bisceglie, David Shapiro
-
Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-13 Sheila L. Noon, Lauren F. Chun, Tin Bo Nicholas Lam, Nhat Quang N. Thai, Winston Dunn, Jeffrey B. Schwimmer
-
Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-13 Vincent Haghnejad, Jean‐Pierre Bronowicki
In 2016, a small retrospective study suggesting that direct-acting agent (DAA) therapy may increase the risk of HCC recurrence created considerable uncertainty around DAA therapy and HCC risk [1]. This uncertainty has persisted for many years despite the publication of subsequent contradictory studies [2, 3]. In this issue, El Serag et al. analysed over 65,000 veterans with compensated cirrhosis, distinguishing
-
The Lipidomic Profile Discriminates Between MASLD and MetALD Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-12 Kai Markus Schneider, Feng Cao, Helen Ye Rim Huang, Lanlan Chen, Yazhou Chen, Rongpeng Gong, Anastasia Raptis, Kate Townsend Creasy, Jan Clusmann, Felix van Haag, Paul‐Henry Koop, Adrien Guillot, Tom Luedde, Rohit Loomba, Sven Francque, Carolin Victoria Schneider
-
Antibiotic Use and Risk of Microscopic Colitis in Older Adults: A Nationwide Self‐Controlled Case Series Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-12 Máté Szilcz, Jonas W. Wastesson, David Bergman, Kristina Johnell, Jonas F. Ludvigsson
-
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-11 Shlomi Cohen, Elizabeth A. Spencer, Michael T. Dolinger, David L. Suskind, Katarina Mitrova, Ondrej Hradsky, Máire A. Conrad, Judith R. Kelsen, Holm H. Uhlig, Christos Tzivinikos, Paul Henderson, Magdalena Wlazlo, Lukas Hackl, Dror S. Shouval, Matteo Bramuzzo, Darja Urlep, Christine Olbjørn, Giulia D'Arcangelo, Gemma Pujol‐Muncunill, Dotan Yogev, Ben Kang, Marco Gasparetto, Christine Rungoe, Kaija‐Leena
-
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-11 Hashem B. El‐Serag, Hao Duong, Michelle Luster, Fasiha Kanwal, Deanna D. Hill, Margaret Burroughs, Candido Hernandez, Barbara A. Haber, Lois M. Larsen, John F. Marcinak, Lani R. Wegrzyn, Jennifer R. Kramer
-
Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Ariel Lee, Kali Zhou
Chronic hepatitis B virus (HBV) infection remains a leading cause of liver disease worldwide, with a risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Currently, nucleoside analogues entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are recommended equally by guidelines as first-line antiviral therapy for chronic HBV and are the most common therapies in high-income countries
-
Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-05 Lingna Ye, Yushu Cao, Yujuan Fu, Chuwen Tian, Qian Cao
-
Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-04 Brian C. Weiner
Careful planning helps to get reliable results and avoids mistakes. The publication by Dulai et al. [1] shows the work involved in a major multicentre project to demonstrate the feasibility for a new treatment in an area sorely lacking in recent innovation. Hyperbaric oxygen (HBO) is purported to be helpful in management of severe inflammatory bowel disease (IBD) due to its known effect of increasing
-
Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV-Infected HCC Patients Undergoing Immunotherapy Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-04 Jialing Wang, Wenjun Meng
We have perused with intrigue the original article by Hung et al., which appraises the efficacy of nucleos/tide analogue (NUC) prophylaxis for downgrading the HBV reactivation (HBVr) in patients with hepatocellular carcinoma (HCC) receiving immunotherapies [1]. Besides, the study emphasised that abnormal baseline alanine aminotransferase (ALT) levels can be identified as a significant risk factor for
-
Letter: Hepatotoxicity in Malignancies Under ICIs Treatment Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-04 Yue Zou, Zhengyu Zhang, Jianjun He
We had the pleasure of reading the research article by Hung et al. [1] We sincerely appreciate their meticulous work and significant contributions, and we hope to offer some constructive suggestions for future research. Firstly, the article provides a comprehensive account of the patients' baseline data and outlines the baseline demographic characteristics of the study population, which is commendable
-
Editorial on ‘Early HBcrAg and Anti-HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’ Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-04 Ming Chao Tsai, Tsung Hui Hu
Cessation of nucleos(t)ide analogue (NA) can lead to the restoration of the immune system and ultimately result in higher rates of functional cure in a selected group of patients with chronic hepatitis B (CHB). However, off-treatment viral relapse is common and may lead to hepatic flares, hepatic decompensation or even death [1-3]. Consequently, identifying biomarkers and high-risk patient characteristics
-
Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-04 Xiaojuan Liu, Xueru Huang, Mingsi Zhang, Tao Jiang, Guangji Zhang
We were intrigued by the study conducted by Amangurbanova et al. [1], which examined the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM) and hyperferritinaemia. The authors proposed elevated serum ferritin as a potential biomarker for MASLD and significant fibrosis, while also elucidating the risk characteristics associated
-
Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-04 Changhu Sun, Zeping Chen, Lincheng Duan
We have carefully reviewed the recently published article, ‘Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk’ [1]. This study highlights the critical role of hepatic steatosis (HS) as a cardiovascular risk enhancer, particularly in individuals traditionally considered to have low-to-intermediate atherosclerotic
-
Letter: Enhancing the Analysis and Clinical Applicability of Ferritin as a Biomarker for MASLD in Type 2 Diabetes Patient Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-04 Pengfei Xi, Hai Li, Shengxian Li
We were very interested to read the article by Amangurbanova et al. published in the Journal [1]. This study provides valuable insights into the association between hyperferritinaemia and metabolic dysfunction-associated steatotic liver disease (MASLD), as well as hepatic fibrosis, in patients with type 2 diabetes mellitus (T2DM). In addition to the limitations the authors mentioned, we believe that
-
Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-03 Michael Camilleri, Alexander C. Ford
-
Editorial: Autoimmune Hepatitis—Could It Be as Easy as Vitamin D? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-01 Jessica K. Dyson
Despite increasing knowledge regarding pathogenesis and risk factors in autoimmune hepatitis (AIH), there is still significant morbidity and mortality associated with both the disease and its treatments. Here, Kilani et al. [1] examine the impact of vitamin D levels on AIH outcomes, stratifying by deficiency, insufficiency and normal levels. This builds on previous work showing links between vitamin
-
Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-01 Courtney Bartel, Phillip Minar
The pharmacokinetics of IBD biologics in children differ from adults. Differences are thought to be related to physiological (e.g., differences in body surface area and a higher rate of hypoalbuminemia), developmental (immature immune processing and higher prevalence of anti-drug antibody formation) and disease-related (e.g., severity and extent of inflammation) factors [1, 2]. Therapeutic drug monitoring
-
Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-02-01 Chia‐Chih Kuo, Chun‐Hsien Li, Min‐Hsiang Chuang, Po‐Yu Huang, Hsing‐Tao Kuo, Chih‐Cheng Lai
-
Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30‐Day Mortality From Acute Pancreatitis Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-31 Maya Fischman, Adi Elias, Amir Klein, Yaron Cohen, Zaher S. Azzam, Itai Ghersin
-
Editorial: Alpha2‐Delta Ligands in Irritable Bowel Syndrome Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-30 Andrea Shin
Irritable bowel syndrome (IBS) is a highly prevalent disorder of gut–brain interaction associated with increased healthcare spending and reduced quality of life. IBS subtypes are defined by bowel patterns, but abdominal pain is a hallmark feature. Few IBS pharmacotherapies specifically target pain. Among these therapies are neuromodulators, particularly tricyclic antidepressants (TCAs), which are recognised
-
Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-28 Kanghee Park, Hye Won Lee, Euichang Kim, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Changhoon Yoo, Baek‐Yeol Ryoo, Seungbong Han, Jonggi Choi
-
Association Between Elevation of Serum Alanine Aminotransferase and HBsAg Seroclearance After Nucleos(t)ide Analog Withdrawal Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-28 Ying‐Nan Tsai, Jia‐Ling Wu, Cheng‐Hao Tseng, Shang‐Chen Tseng, Chih‐Lung Hung, Mindie H. Nguyen, Jaw‐Town Lin, Yao‐Chun Hsu
-
The Impact of Postoperative Prophylactic Medication on Long-Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-24 Sebastiaan ten Bokkel Huinink, Michiel T. J. Bak, Evelien M. J. Beelen, Nicole S. Erler, Mark S. Silverberg, Matthieu Allez, Frank Hoentjen, Alexander G. L. Bodelier, Gerard Dijkstra, Marielle Romberg-Camps, Nanne K. H. de Boer, Laurents P. S. Stassen, Andrea E. van der Meulen – de Jong, Rachel L. West, C. Janneke van der Woude, Oddeke van Ruler, Annemarie C. de Vries
-
Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-24 Lichao Qiao, Bolin Yang
We thank Drs Parian and Schwartz for their insightful editorial on our study [1]. Patients presenting with perianal fistulae experience a significantly worse long-term prognosis when there is a delay in diagnosing Crohn's disease (CD) [2]. However, clinical decision-making tools for the early identification of patients with perianal fistulae at risk of CD are currently lacking in practice. The present
-
Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-24 Alyssa M. Parian, David A. Schwartz
Perianal fistulising Crohn's disease (PFCD) is found in up to 25% of patients with CD and is associated with decreased quality of life and increased healthcare expenditures. Approximately 11.5% of patients with CD present with perianal fistula (PAF) as their first symptom [1]. Furthermore, 4%–5% of patients have isolated PAF as their only manifestation [2]. Prolonged time to diagnosis of CD in patients
-
Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-24 Pojsakorn Danpanichkul, Donghee Kim, Markos Kalligeros, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha
We deeply appreciate the insightful letter from Liu and He et al., which highlights their analysis of the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD)-related liver cancer using the Global Burden of Disease Study (GBD) 2021 database [1]. The similarities between their findings and our observations on the rising burden of MASLD-related liver cancer in the United
-
Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021 Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-24 Chunlong Liu, Ziqiang He, Jiangtao Yu, Rui Yang
We read with great interest the study by Danpanichkul et al. [1], which conducted an in-depth analysis of the burden of primary liver cancer (PLC) in the United States from 2000 to 2021. The results revealed that PLC incidences increased by 141% and deaths by 136%. The age-standardised incidence rate (ASIR) and age-standardised death rate (ASDR) for PLC also rose, primarily driven by alcohol-related
-
Issue Information Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-23
Click on the article title to read more.
-
Letter: Toward Intra-Class Switching With JAK Inhibitors? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-23 Mathieu Uzzan, David Laharie
Akiyama et al. reported the real-world effectiveness of three JAK inhibitors in a Japanese multicentre cohort of 602 patients with ulcerative colitis (UC); 228, 215 and 159 patients, respectively, were treated with upadacitinib, filgotinib and tofacitinib [1]. Among these patients, 106 (46%) in the upadacitinib group, 30 (14%) in the filgotinib group and none in the tofacitinib group had prior exposure
-
Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States—Author's Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-23 Pojsakorn Danpanichkul, Donghee Kim, Chun Wei Pan, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha
We extend our sincere gratitude for the recent editorial highlighting our manuscript [1]. In our study titled ‘Alcohol-Related Liver Disease, Followed by Metabolic Dysfunction-Associated Steatotic Liver Disease, Emerges as the Fastest-Growing Aetiologies for Primary Liver Cancer in the United States’, we analysed the prevalence, incidence and mortality trends of primary liver cancer (PLC) in the United
-
Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-23 Kelly Torosian, Veeral Ajmera
With the advent of direct-acting antiviral agents for hepatitis C (HCV) in 2013 and increased uptake of vaccines for hepatitis B, the burden of viral-related chronic liver disease has significantly decreased [1, 2]. It was predicted that this would lead to a plateau or even decrease in the incidence of primary liver cancer (PLC) especially in younger cohorts and specific ethnic groups [3-5]. However
-
Letter: Toward Intra-Class Switching With JAK Inhibitors? Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-23 Shintaro Akiyama, Toshimitsu Fujii
We thank Dr. Uzzan et al. [1] for their comments on our publication [2]. We have clarified the data availability regarding intra-class switching with Janus kinase (JAK) inhibitors in our study (Figure 1). We demonstrated the efficacy of upadacitinib in ulcerative colitis (UC) after the use of tofacitinib and filgotinib [2]. As a result, upadacitinib-treated patients showed a clinical remission rate
-
Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S. Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-23 Aakash Desai, Priya Sehgal, Himsikhar Khataniar, James D. Lewis, Francis A. Farraye, Gary R. Lichtenstein, Gursimran S. Kochhar
-
Letter: Enhancing HCC Surveillance–GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-22 Ibrahima Gueye
We read with interest the article by Shiha et al., titled ‘Individualized HCC Surveillance Using Risk Stratification Scores in Advanced Fibrosis and Cirrhotic HCV Patients Who Achieved SVR: A Prospective Study’ [1]. As a board member of World Hepatitis Alliance representing African region and as a patient who developed cirrhosis, I was fortunate to receive liver transplantation in time following diagnosis
-
Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-22 Gamal Shiha, Riham Soliman
We would like to express our appreciation to Dr. Gueye, World Hepatitis Alliance Afro Regional Board Member and Honour President of Saafara Hépatites Sénégal, for his insightful letter on the advantages of the General Evaluation Score (GES) in hepatocellular carcinoma (HCC) surveillance [1]. We agree with him that the GES score simplicity and practicality as a bedside tool make it accessible and easy
-
Review Article: Rome Foundation Working Team Report: Consensus Statement on the Design and Conduct of Behavioural Clinical Trials for Disorders of Gut–Brain Interaction Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-21 Helen Burton-Murray, Livia Guadagnoli, Kendra Kamp, Inês A. Trindade, Lynda H. Powell, Magnus Simrén, Brjánn Ljótsson, Laurie Keefer
-
Retrospective Cohort Study: Scope for Improvement—Barriers to Post-Polypectomy Surveillance in the Integrated Technologies for Improved Polyp Surveillance Cohort Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-20 Charlotte Mathews, Aleena Nauman, Mark Johnstone, Reiss Stoops, Alexander Tham, Emma C. Parsons, Kathryn A. Robb, William Sloan, Gerard Lynch, Joanne Edwards, Stephen T. McSorley
-
Network Meta‐Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-18 Mohammad Shehab, Ahmed Al‐Hindawi, Fatema Alrashed, Sanjay Murthy, Raf Bisschops, Frank Hoentjen, Alan Barkun, Siddharth Singh, Talat Bessissow
-
Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-18 Federica Tavaglione, Maral Amangurbanova, Alexander H. Yang, Monica A. Tincopa, Veeral Ajmera, Lisa Richards, Christian Butcher, Christie Hernandez, Egbert Madamba, Seema Singh, Ricki Bettencourt, Claude B. Sirlin, Rohit Loomba
-
Editorial: Safety and Effects of Direct Oral Anticoagulants for Portal Vein Thrombosis Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-18 Nina Kimer, Lise Hobolth, Lise Lotte Gluud
Portal vein thrombosis (PVT) is a serious complication in chronic liver disease, mainly occurring in patients with portal hypertension [1]. The pathophysiology of PVT includes a combination of venous stasis, hypercoagulability and endothelial dysfunction, leading to reduced portal flow velocity and stagnation of blood in the splanchnic circulation [2, 3]. PVT is associated with a range of complications
-
Disparities in Alcohol‐Associated Liver Disease Hospital Encounters Amongst a Texas‐Based Cohort of Patients Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2025-01-17 Thomas G. Cotter, Ahmad Anouti, Bill Zhang, Elias D. Rady, Mausam Patel, Suraj Patel, Daniel J. Ellis, Sarah R. Lieber, Nicole E. Rich, Jacqueline G. O'Leary, Mack C. Mitchell, Amit G. Singal